64.92
price up icon0.95%   0.61
after-market 시간 외 거래: 64.95 0.03 +0.05%
loading
전일 마감가:
$64.31
열려 있는:
$64.75
하루 거래량:
8.25M
Relative Volume:
0.85
시가총액:
$220.09B
수익:
$43.59B
순이익/손실:
$15.04B
주가수익비율:
19.23
EPS:
3.3766
순현금흐름:
$10.74B
1주 성능:
-5.83%
1개월 성능:
-12.00%
6개월 성능:
-19.88%
1년 성능:
-50.65%
1일 변동 폭
Value
$64.12
$65.33
1주일 범위
Value
$64.12
$69.49
52주 변동 폭
Value
$57.00
$139.74

노보 노디스크 Stock (NVO) Company Profile

Name
명칭
Novo Nordisk Adr
Name
전화
-
Name
주소
-
Name
직원
77,406
Name
트위터
@novonordisk
Name
다음 수익 날짜
2024-12-06
Name
최신 SEC 제출 서류
Name
NVO's Discussions on Twitter

NVO을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
64.92 306.33B 43.59B 15.04B 10.74B 3.3766
Drug Manufacturers - General icon
LLY
Lilly Eli Co
762.18 717.60B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
164.36 377.32B 90.63B 22.66B 18.57B 9.35
Drug Manufacturers - General icon
ABBV
Abbvie Inc
184.85 338.30B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
114.14 234.32B 55.19B 13.65B 16.81B 6.86

노보 노디스크 Stock (NVO) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-04-17 다운그레이드 BMO Capital Markets Outperform → Market Perform
2025-03-13 업그레이드 Kepler Hold → Buy
2025-03-03 다운그레이드 Stifel Buy → Hold
2025-02-12 개시 Morgan Stanley Equal-Weight
2025-01-06 업그레이드 Bernstein Underperform → Mkt Perform
2024-05-30 개시 Goldman Buy
2024-04-12 개시 BMO Capital Markets Outperform
2024-01-23 개시 Morgan Stanley Overweight
2024-01-16 재개 UBS Neutral
2023-12-01 개시 Cantor Fitzgerald Overweight
2023-10-02 개시 Argus Buy
2023-07-14 개시 HSBC Securities Buy
2022-07-15 업그레이드 Morgan Stanley Equal-Weight → Overweight
2022-06-28 다운그레이드 UBS Neutral → Sell
2022-06-27 업그레이드 Exane BNP Paribas Underperform → Neutral
2022-06-07 업그레이드 JP Morgan Neutral → Overweight
2022-05-31 업그레이드 Guggenheim Neutral → Buy
2022-04-25 업그레이드 Cowen Market Perform → Outperform
2022-04-12 업그레이드 Morgan Stanley Underweight → Equal-Weight
2022-03-16 업그레이드 Deutsche Bank Hold → Buy
2022-01-25 다운그레이드 Liberum Hold → Sell
2021-12-20 다운그레이드 JP Morgan Overweight → Neutral
2021-12-17 다운그레이드 Deutsche Bank Buy → Hold
2021-01-20 다운그레이드 Credit Suisse Outperform → Neutral
2021-01-15 개시 Deutsche Bank Buy
2020-09-29 개시 Berenberg Hold
2020-07-06 다운그레이드 BofA Securities Buy → Neutral
2020-05-11 다운그레이드 UBS Buy → Neutral
2020-05-04 개시 Cowen Market Perform
2020-03-16 업그레이드 BofA/Merrill Neutral → Buy
2020-01-03 다운그레이드 Guggenheim Buy → Neutral
2019-11-18 업그레이드 Barclays Equal Weight → Overweight
2019-09-17 업그레이드 Citigroup Neutral → Buy
2019-08-30 다운그레이드 Jefferies Hold → Underperform
2019-06-20 다운그레이드 Deutsche Bank Buy → Hold
2019-06-11 업그레이드 Barclays Underweight → Equal Weight
2019-04-29 업그레이드 Credit Suisse Neutral → Outperform
2019-01-29 개시 Exane BNP Paribas Outperform
2018-12-11 재개 Jefferies Hold
2018-10-09 개시 Guggenheim Buy
2017-12-29 업그레이드 JP Morgan Underweight → Neutral
2017-12-06 업그레이드 BofA/Merrill Neutral → Buy
2017-12-01 업그레이드 Morgan Stanley Equal-Weight → Overweight
2017-09-25 다운그레이드 Exane BNP Paribas Outperform → Neutral
2017-09-06 업그레이드 BofA/Merrill Underperform → Neutral
모두보기

노보 노디스크 주식(NVO)의 최신 뉴스

pulisher
08:15 AM

2 Undervalued Healthcare Stocks Poised to Dominate the Next Decade - The Motley Fool

08:15 AM
pulisher
Jul 16, 2025

HIMS & HERS HEALTH SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - GlobeNewswire Inc.

Jul 16, 2025
pulisher
Jul 16, 2025

Novo Nordisk’s GLP-1 Reign Faces New Pressures In 2025 - Finimize

Jul 16, 2025
pulisher
Jul 15, 2025

HIMS & HERS HEALTH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Against Hims & Hers Health, Inc. - GlobeNewswire Inc.

Jul 15, 2025
pulisher
Jul 15, 2025

NVO’s 2025 Market Dance: Down -51.70% – Time to Invest? - investchronicle.com

Jul 15, 2025
pulisher
Jun 24, 2025

Novo Nordisk's Cardiometabolic Foundation Supports Wide Moat - Morningstar

Jun 24, 2025
pulisher
Jun 22, 2025

Novo Nordisk: Navigating Challenges to Dominate Diabetes and Obesity Therapies - AInvest

Jun 22, 2025
pulisher
Jun 19, 2025

The Skinny On Novo Nordisk: This Slimmed-Down Stock May Be Worth A... Shot - Finimize

Jun 19, 2025
pulisher
Jun 17, 2025

NVO’s Stock Woes: Down -31.04% in 6 Months, Down -31.04% in Just 5 Days - investchronicle.com

Jun 17, 2025
pulisher
Jun 16, 2025

European Stocks Shine As ADRs Climb Higher - Finimize

Jun 16, 2025
pulisher
Jun 13, 2025

After ousting CEO, Novo Nordisk reclaims crown as largest European company - MSN

Jun 13, 2025
pulisher
Jun 10, 2025

Why Novo Nordisk Stock Just Popped - Barchart.com

Jun 10, 2025
pulisher
May 31, 2025

European ADRs Show Strength With Genfit And Novo Nordisk Leading Gains - Finimize

May 31, 2025
pulisher
May 30, 2025

European ADRs Show Resilience In US Market - Finimize

May 30, 2025
pulisher
May 19, 2025

Novo Nordisk Faces Obesity Competition, but Innovation Still Warrants a Wide Moat - Morningstar

May 19, 2025
pulisher
May 19, 2025

Bio/Pharmaceutical Outsourcing Report, March 2025 Edition - GlobeNewswire Inc.

May 19, 2025
pulisher
May 16, 2025

European ADRs Dip As Pharma And Tech Stocks See Mixed Results - Finimize

May 16, 2025
pulisher
May 13, 2025

What Did We Find About Insider Trading At Novo Nordisk ADR (NYSE: NVO)? - Stocksregister

May 13, 2025
pulisher
May 10, 2025

European Stocks Show Mixed Results With Novo Nordisk Leading Gains - Finimize

May 10, 2025
pulisher
May 09, 2025

Novo Nordisk Q1 Earnings Match Estimates, Revenues Rise Y/Y, Stock Up - MSN

May 09, 2025
pulisher
May 08, 2025

Novo Nordisk ADR earnings beat by $5.64, revenue topped estimates - Investing.com Nigeria

May 08, 2025
pulisher
May 07, 2025

Novo Nordisk Earnings: Compounders Pressured Q1 Wegovy Sales - Morningstar

May 07, 2025
pulisher
May 07, 2025

Novo Nordisk Earnings: Compounders Pressured Q1 Wegovy Sales, but Strategy Should Preserve Growth - Morningstar

May 07, 2025
pulisher
May 07, 2025

European ADRs See Mixed Results With Modest Gains - Finimize

May 07, 2025
pulisher
May 07, 2025

Novo Nordisk expects U.S. sales of Wegovy weight-loss drug to recover soon, CEO says - The Globe and Mail

May 07, 2025
pulisher
May 07, 2025

Market news - investments.halifax.co.uk

May 07, 2025

노보 노디스크 (NVO) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
drug_manufacturers_general MRK
$79.31
price down icon 0.81%
drug_manufacturers_general NVS
$114.14
price down icon 0.10%
$295.87
price up icon 0.38%
drug_manufacturers_general PFE
$24.26
price down icon 0.86%
$108.28
price up icon 0.06%
자본화:     |  볼륨(24시간):